Search Results 131-140 of 16530 for Cirrhosis
Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) · Overview.
The purose of this study is to assess the effectiveness, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia. Participation ...
Specialists in pediatric hepatology and liver transplant diagnose and treat children with liver disease. Advanced diagnosis and treatment. You'll have access to ...
Mayo Clinic researcher Enis Kostallari, Ph.D., M.S., focuses on the molecular mechanisms of liver fibrosis, subsequent cirrhosis and the terminal stage of ...
In some cases, nonalcoholic fatty liver disease eventually can damage the liver to the point that cirrhosis develops. This serious and sometimes life- ...
About this study. The purpose of this study is to evaluate the effects of two doses of MBX-8025 in patients with primary biliary cirrhosis and an inadequate ...
Progressive liver damage in the form of extensive fibrosis, or liver scarring, called "cirrhosis," occurs in about 25 percent of people with hepatitis C. The ...
... cirrhosis, with at least one of the following: - There is a historical liver biopsy showing cirrhosis with steatohepatitis. There is no evidence for a ...
The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.
NASH is the aggressive form of fatty liver, which leads to progression to cirrhosis and end-stage liver disease if not diagnosed and treated. She leads the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.